Exit
In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 100% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements. 

There is no fee to participate in this activity.

Question Title

* 1. What are your credentials?

Question Title

* 2. What is your community of practice?

Question Title

* 3. Which of the following is the leading cause of death in patients with #MultipleMyeloma? 

Question Title

* 4. 72 yo/F dx w/ IgA MM. She will begin lymphodepletion  with fludarabine and cyclophosphamide tomorrow prior to idecabtagene vicleucel infusion. Which of the following should be started to prevent infection? 

Question Title

* 5. 63 yo/M on cycle 6 teclistamab. He received acyclovir & sulfamethoxazole/trimethoprim prophylaxis. He was hospitalized for streptococcus pneumoniae pneumonia & tx w/ cefepime. IgG level is 1.4 g/L. Which of the following should be added to his regimen? 

EVALUATION FORM

Question Title

* 6. Upon completion of this activity, I am able to:

  Strongly agree Agree Disagree Strongly disagree
TRANSLATE strategies to monitor and minimize the negative impact of treatment-related toxicities for BCMA-directed therapies in RRMM

Question Title

* 7. Please indicate the extent of your agreement with the following statements:

  Strongly agree Agree Disagree Strongly disagree
The faculty for this activity were effective
The educational resources provided to me at the educational activity are useful to my practice.

Question Title

* 8. Overall, was this activity fair, balanced and free from commercial bias?

Question Title

* 9. If no, please explain:

Question Title

* 10. Of the patients you will see in the next month, about how many will benefit from the information you learned today?

Question Title

* 11. Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):

Question Title

* 12. Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):

Question Title

* 13. As a result of what I learned, I intend to make changes in my practice:

Question Title

* 14. What change(s) will you incorporate into your practice as a result of what you have learned in this activity?

Question Title

* 15. If you are claiming credit, please provide your contact information so we can send your certificate. Certificates will be provided within 4-6 weeks.

Question Title

* 16. I certify that I have participated in the continuing education activity entitled, "Acute Toxicities with BCMA-directed T-cell therapies" and claim 0.25 AMA PRA Category 1 CreditTM.

Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate. 

For information about the certification of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
( Privacy & Cookie Notice

T